Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment

被引：0
|
作者：
Wang, Michael L. [1 ]
Shah, Nirav N. [2 ]
Jurczak, Wojciech [3 ,6 ]
Zinzani, Pier Luigi [4 ,5 ]
Eyre, Toby A.
Cheah, Chan Y. [7 ,8 ,9 ]
Ujjani, Chaitra S. [10 ]
Izutsu, Koji [11 ]
Ma, Shuo [12 ]
Flinn, Ian [13 ]
Alencar, Alvaro J. [14 ]
Lewis, David [15 ]
Patel, Krish [16 ]
Maddocks, Kami [17 ]
Wang, Yucai [18 ]
Munir, Talha [19 ]
Zelenetz, Andrew D. [20 ]
Balbas, Minna [21 ]
Tsai, Donald E. [21 ]
Wang, Chunxiao [22 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland
[4] IRCCS Azienda Osped Univ Bologna Ist Ematol, Seragnoli, Italy
[5] Univ Bologna, Dipartimento Med Specialist Diag & Sperimentale, Bologna, Italy
[6] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England
[7] Linear Clin Res, Perth, WA, Australia
[8] Sir Charles Gairdner Hosp, Perth, WA, Australia
[9] Univ Western Australia, Med Sch, Perth, WA, Australia
[10] Univ Washington, Fred Hutchinson Canc Res Ctr, Washington, DC USA
[11] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
[12] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[13] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA
[14] Sylvester Comprehens Canc Ctr, Miami, FL USA
[15] Plymouth Hosp NHS Trust Derriford Hosp, Plymouth, Devon, England
[16] Swedish Canc Inst, Ctr Blood Disorders & Cellular Therapy, Seattle, WA USA
[17] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[18] Mayo Clin, Div Hematol, Rochester, MN USA
[19] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England
[20] Memorial Sloan Kettering Canc Ctr, New York, NY USA
[21] Loxo Lilly, Indianapolis, IN USA
[22] Eli Lilly & Co, Indianapolis, IN USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
MCL; BTK-inhibitor; pirtobrutinib; TP53; mutation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MCL-155
引用
收藏
页码：S459 / S459
页数：1
相关论文
共 50 条
  • [41] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 10 - 11
  • [42] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
    Wang, Michael
    Shah, Nirav N.
    Alencar, Alvaro J.
    Gerson, James N.
    Patel, Manish R.
    Fakhri, Bita
    Jurczak, Wojciech
    Tan, Xuan Ni
    Lewis, Katharine L.
    Fenske, Timothy S.
    Coombs, Catherine C.
    Flinn, Ian W.
    Lewis, David John
    Le Gouill, Steven
    Palomba, M. Lia
    Woyach, Jennifer A.
    Pagel, John M.
    Lamanna, Nicole
    Cohen, Jonathon B.
    Barve, Minal
    Ghia, Paolo
    Eyre, Toby A.
    Yin, Ming
    Nair, Binoj
    Tsai, Donald
    Ku, Nora C.
    Mato, Anthony
    Cheah, Chan Yoon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 11 - 12
  • [43] Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results
    Cohen, Jonathon B.
    Shah, Nirav N.
    Alencar, Alvaro J.
    Gerson, James N.
    Patel, Manish R.
    Fahkri, Bita
    Jurczak, Wojciech
    Tan, Xuan N.
    Lewis, Katharine L.
    Fenske, Timothy S.
    Coombs, Catherine C.
    Flinn, Ian
    Lewis, David J.
    Le Gouill, Stephen
    Palomba, M. Lia
    Woyach, Jennifer A.
    Pagel, John M.
    Lamanna, Nicole
    Barve, Minal A.
    Ghia, Paolo
    Eyre, Toby A.
    Yin, Ming
    Nair, Binoj
    Tsai, Donald E.
    Ku, Nora C.
    Mato, Anthony R.
    Cheah, Chan Y.
    Wang, Michael L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S378 - S379
  • [44] Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study
    Eyre, Toby
    Pagel, John M.
    Coombs, Catherine C.
    Shah, Nirav N.
    Lamanna, Nicole
    Lech-Maranda, Ewa
    Woyach, Jennifer
    Wierda, William G.
    Cheah, Chan Y.
    Roeker, Lindsey
    Patel, Manish R.
    Fakhri, Bita
    Barve, Minal A.
    Tam, Constantine S.
    Lewis, David
    Gerson, James N.
    Alencar, Alvaro
    Taylor, Justin
    Abedel-Wahab, Omar
    Ghia, Paolo
    Schuster, Stephen J.
    Chen, Jessica
    Nair, Binoj
    Tsai, Donald E.
    Ku, Nora C.
    Davids, Matthew S.
    Brown, Jennifer R.
    Jurczak, Wojciech
    Mato, Anthony R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 37 - 38
  • [45] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)
    Mehta, Amitkumar
    Trneny, Marek
    Walewski, Jan
    Ribrag, Vincent
    Dartigeas, Caroline
    Christensen, Jacob Haaber
    Pane, Fabrizio
    Rodriguez, Guillermo
    Taszner, Michal
    Venugopal, Parameswaran
    Zilioli, Vittorio Ruggero
    Zheng, Fred
    DeMarini, Douglas J.
    Jiang, Wei
    Zinzani, Pier Luigi Luigi
    BLOOD, 2021, 138
  • [46] Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated With a BTK Inhibitor: Primary Analysis From a Phase 2 Study (CITADEL-205)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 11 - 13
  • [47] LOTIS-2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine (Lonca) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Kahl, Brad S.
    Hamadani, Mehdi
    Caimi, Paolo F.
    Carlo-Stella, Carmelo
    Ai, Weiyun
    Alderuccio, Juan Pablo
    Ardeshna, Kirit M.
    Hess, Brian
    Radford, John
    Solh, Melhem
    Stathis, Anastasios
    Feingold, Jay
    Ungar, David
    Qin, Yajuan
    He, Shui
    Zinzani, Pier Luigi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S377 - S378
  • [48] Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
    S Rule
    W Jurczak
    M Jerkeman
    C Rusconi
    M Trneny
    F Offner
    D Caballero
    C Joao
    M Witzens-Harig
    G Hess
    I Bence-Bruckler
    S-G Cho
    C Thieblemont
    W Zhou
    T Henninger
    J Goldberg
    J Vermeulen
    M Dreyling
    Leukemia, 2018, 32 : 1799 - 1803
  • [49] Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
    Rule, S.
    Jurczak, W.
    Jerkeman, M.
    Rusconi, C.
    Trneny, M.
    Offner, F.
    Caballero, D.
    Joao, C.
    Witzens-Harig, M.
    Hess, G.
    Bence-Bruckler, I.
    Cho, S-G
    Thieblemont, C.
    Zhou, W.
    Henninger, T.
    Goldberg, J.
    Vermeulen, J.
    Dreyling, M.
    LEUKEMIA, 2018, 32 (08) : 1799 - 1803
  • [50] Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study
    Wang, Michael
    Rule, Simon
    Martin, Peter
    Goy, Andre
    Auer, Rebecca
    Kahl, Brad S.
    Jurczak, Wojciech
    Advani, Ranjana
    Romaguera, Jorge E.
    Williams, Michael E.
    Barrientos, Jacqueline C.
    Chmielowska, Ewa
    Radford, John
    Stilgenbauer, Stephan
    Dreylingls, Martin
    Jedrzejczak, Wieslaw Wiktor
    Johnson, Peter W.
    Spurgeon, Stephen E.
    Zhang, Liang
    Baher, Linda
    Cheng, Mei
    Beaupre, Darrin M.
    Blum, Kristie A.
    BLOOD, 2014, 124 (21)
12345